Virax Biolabs Announces the Appointment of Jason D. Davis as Chief Financial Officer
London, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited (“Virax” or the “Company”) is pleased to announce the appointment of Jason D. Davis to the role of Chief Financial Officer, effective immediately. Mr. Davis brings over 20 years of multi-disciplinary experience leading the accounting and finance functions and holding executive management positions at several public and private companies.
"On behalf of our board and management team, I am extremely pleased to welcome Jason to Virax,” commented James Foster, Chief Executive Officer of Virax. “His appointment is an important step in our efforts to prepare the Company as a publicly traded company. Jason brings with him a wealth of public company experience in the role of chief financial officer and will be instrumental as we execute our business plan going forward. We look forward to Jason becoming an integral part of Virax's leadership team."
“I am honored to be joining the leadership team at Virax at such an exciting time for the Company,” stated Mr. Davis. “Thanks to its outstanding technology, Virax is well positioned in lucrative and growing market sectors within immunology and in-vitro diagnostic medical devices, and I am excited to work with the team to implement and realize Virax's growth strategy and financial goals.”
Mr. Davis is a licensed Certified Public Accountant and has served in various leadership and executive roles for several companies, including as a vice president of finance and treasurer of Hyperdynamics Corporation (OTC: HDYNQ) and Casa Exploration, LLC and more recently as a vice president of finance of Durango Midstream LLC and an interim chief financial officer of Yuma Energy, Inc. (OTC: YUMAQ). Mr. Davis received his Bachelor of Business Administration degree in Accounting from the University of Houston in 1997.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology.
Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. For more information, please visit www.viraxbiolabs.com.
Safe Harbor Statement
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Company Contact:
Virax Biolabs Group Limited
Karen Bertoli, Advisor
Phone: +1.205.216.4190
Email: kb@viraxlabs.com
Investor Relations Contact:
Skyline Corporate Communications Group, LLC
Lisa Gray, Senior Account Manager
One Rockefeller Plaza, 11th Floor
New York, NY 10020
Office: 1 (646) 893-5835
Email: lisa@skylineccg.com
Released April 28, 2022